Aspirin Provides No Benefit for Breast Cancer Recurrence, Survival
Findings seen among people with high-risk nonmetastatic breast cancer at a median 33.8 months.
Source: empr.com
Stay updated with breaking news from Wendyy Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings seen among people with high-risk nonmetastatic breast cancer at a median 33.8 months.
A new study found that taking aspirin as adjuvant therapy does not improve outcomes for patients with high-risk nonmetastatic breast cancer.
Compared with placebo, daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer.
Daily aspirin use did not improve invasive disease-free survival in patients with HER2-negative breast cancer in a phase 3 trial.
Trend toward higher recurrence rate in large randomized trial